Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Vaccinex Inc (NQ: VCNX )

5.931 +0.926 (+18.50%)
Streaming Delayed Price Updated: 3:39 PM EDT, Apr 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 8,667
Open 5.750
Bid (Size) 5.230 (1)
Ask (Size) 6.090 (2)
Prev. Close 5.005
Today's Range 5.400 - 5.950
52wk Range 0.5115 - 10.10
Shares Outstanding 65,941,086
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
VCNX Stock Earnings: Vaccinex Reported Results for Q4 2023
Vaccinex just reported results for the fourth quarter of 2023. 
Via InvestorPlace

Performance

YTD
+686.83%
+686.83%
1 Month
-21.44%
-21.44%
3 Month
+904.93%
+904.93%
6 Month
+487.24%
+487.24%
1 Year
+12.49%
+12.49%

More News

Read More
Vaccinex Reports 2023 Financial Results and Provides Corporate Update
From Vaccinex, Inc.
Via GlobeNewswire
Vaccinex, Inc. Announces $1.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules
From Vaccinex, Inc.
Via GlobeNewswire
Why Vaccinex (VCNX) Stock Is Trading Lower
Via Benzinga
Why Vaccinex (VCNX) Stock Is Popping Off
Via Benzinga
Vaccinex Announces Multiple New Agreements for Access to ActivMAb® Antigen Virus Technology
From Vaccinex, Inc.
Via GlobeNewswire
Vaccinex, Inc. Announces Reverse Stock Split
From Vaccinex, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
Vaccinex Announces Pricing of $3.7 Million PIPE Financing
From Vaccinex, Inc.
Via GlobeNewswire
Nasdaq Grants Vaccinex Extension Until March 4, 2024 to Regain Compliance with Listing Rule
From Vaccinex, Inc.
Via GlobeNewswire
Vaccinex Reports Third Quarter 2023 Financial Results and Provides Corporate Update
From Vaccinex, Inc.
Via GlobeNewswire
Vaccinex Reports Clinical Benefit in Interim Analyses from two Phase 2 Studies of Pepinemab Combination Treatment at Society for Immunotherapy of Cancer’s Annual Meeting
From Vaccinex, Inc.
Via GlobeNewswire
Vaccinex Reports Positive Effect of Pepinemab Treatment on New Biomarker of Brain Inflammation in Neurodegenerative Diseases
From Vaccinex, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Gold Moves Higher; OMNIQ Shares Plunge
Via Benzinga
Topics Stocks
Exposures US Equities
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Why ParaZero Technologies Shares Are Trading Higher By Over 100%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Why Is Near Intelligence (NIR) Stock Down 20% Today?
Via InvestorPlace
Why CalAmp Shares Are Trading Lower By Around 32%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Via Benzinga
Why Is Omniq (OMQS) Stock Down 43% Today?
Via InvestorPlace
Why Pioneer Natural Resources Shares Are Bouncing By Around 12%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.